Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM)

Price 305.00p on 28-11-2023 at 17:30:02
Change 0.00p 0%
Buy 306.50p
Sell 305.00p
Buy / Sell HCM Shares
Last Trade: Unknown 3,226.00 at 306.025p
Day's Volume: 140,534
Last Close: 305.00p
Open: 311.50p
ISIN: KYG4672N1198
Day's Range 305.00p - 312.00p
52wk Range: 173.60p - 338.00p
Market Capitalisation: £2,657m
VWAP: 304.85218p
Shares in Issue: 871m

Recent Trades History Hutchmed (HCM)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 3,226 306.025p Ordinary
Currency Conversion
OTC Trade
17:09:42 - 28-Nov-23
Sell* 5,000 305.00p Negotiated Trade
16:37:12 - 28-Nov-23
Sell* 10,000 305.00p Automatic Execution
16:36:47 - 28-Nov-23
Sell* 9,750 305.51282p Negotiated Trade
16:36:30 - 28-Nov-23
Sell* 10,000 305.50p Negotiated Trade
16:36:13 - 28-Nov-23
Sell* 12,500 305.00p Uncrossing Trade
16:35:02 - 28-Nov-23
Buy* 49 306.50p Automatic Execution
16:29:45 - 28-Nov-23
Buy* 144 306.50p Automatic Execution
16:29:40 - 28-Nov-23
Sell* 496 306.00p Automatic Execution
16:25:49 - 28-Nov-23
Sell* 3,720 306.00p Automatic Execution
16:25:45 - 28-Nov-23

Share Price History for Hutchmed

Time period:
Date Open High Low Close Volume

Share News for Hutchmed

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

9th Nov 2023 12:16

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer. Read More

Hutchmed notes Takeda submits fruquintinib drug application in Japan

29th Sep 2023 10:12

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquintinib to the Ministry of Health, Labour & Welfare in Japan. Read More

IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat

12th Sep 2023 10:26

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase two study in China to evaluate the efficacy of cancer drug Tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma. Tazemetostat is approved by the US Food & Drug Administration for the treatment of advanced epithelioid sarcoma and R/R FL. Read More

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

29th Aug 2023 09:30

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options. Read More

Hutchmed China hails trial on sovleplenib meeting primary endpoint

21st Aug 2023 08:46

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint. Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered